Dihexa

Dihexa is a small synthetic molecule derived from angiotensin IV, a fragment of the hormone system best known for regulating blood pressure. It was developed at Washington State University, and its story is a good illustration of how a research compound can end up somewhere other than where it started.

The renin–angiotensin system controls blood pressure and fluid balance, and angiotensin II is its main effector. Angiotensin IV is a shorter fragment of the same molecule, and it was noticed that this fragment had effects on learning and memory in animals that had nothing to do with blood pressure. Work on why produced a series of increasingly modified analogues, of which Dihexa is the most potent.

The mechanism eventually identified was not the one anyone expected. Rather than acting through an angiotensin receptor, Dihexa appears to work on hepatocyte growth factor and its receptor c-Met — a signalling system named for its role in the liver and subsequently found to matter a great deal in the nervous system. The compound is best understood as an HGF potentiator with an angiotensin ancestry.

• Potentiation rather than activation: It is reported to amplify the effect of hepatocyte growth factor already present rather than to activate the receptor by itself. Amplifying an existing signal is mechanistically distinct from imposing a new one.

• Synapse formation: HGF signalling is involved in building new connections between neurons. Studies have measured the density of dendritic spines — the physical points of contact — which is a concrete structural endpoint rather than a behavioural one.

• Reported potency: Published comparisons describe it as active at very low concentrations relative to BDNF in the same assays. Claims of that magnitude are exactly the kind that need independent replication.

• An unexpected mechanism: A compound designed from one hormone system turning out to act on another is instructive in itself, and a reminder of how often the mechanism of an effective molecule is discovered after the effect.

Learning changes the brain physically. Neurons communicate at synapses, and forming a memory involves strengthening existing synapses and building new ones. The connection points sit on small protrusions called dendritic spines, and their number and shape can be counted under a microscope — which makes this one of the few areas of cognitive research with a directly visible structural measure.

Hepatocyte growth factor is one of the signals governing that construction. Despite the name, which reflects where it was first found, HGF and its receptor c-Met are active in the nervous system and involved in the growth of neural processes and the formation of synapses. It is a builder's signal.

Dihexa is reported to increase the effect of HGF that is already there rather than to act on the receptor independently. The practical difference is significant: a potentiator can only work where the natural signal is present, so its effect is shaped by existing biology rather than applied uniformly. That is a more targeted kind of intervention in principle, and also a harder one to characterise, since the result depends on conditions the experimenter does not fully control.

The published work comes from academic laboratories and is peer-reviewed, reporting improvements on rodent memory tasks and increased dendritic spine density. The link to HGF/c-Met signalling is supported by several studies. This is a properly documented preclinical compound rather than a supplier invention.

The work is entirely preclinical, with no human trials and no approved use, and most of it originates from the group that developed the compound. It is supplied for laboratory research only. One point belongs in any study design: c-Met signalling drives cell growth and is implicated in several cancers, so a compound amplifying it raises questions the cognition work was not built to address.

P021 is the natural comparison — another designed compound aimed at neurotrophic signalling, working by prompting the brain to raise its own BDNF rather than by amplifying a growth factor. Same objective, different pathway, similar stage of evidence.

Semax approaches the same territory from the Russian peptide tradition, with a far larger but less independently replicated body of work behind it.